TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.

Jens Huober et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.